Clinical Edge Journal Scan

Breast-conserving surgery may benefit BC patients with multiple tumors in the same breast


 

Key clinical point: In women with 2-3 ipsilateral foci of breast cancer (BC), breast-conserving surgery (BCS; lumpectomy plus adjuvant radiation) resulted in a local recurrence rate that was below the a priori determined clinically acceptable threshold of 8%.

Major finding: BCS resulted in a highly acceptable 5-year local recurrence rate of 3.1% (95% CI 1.3%-6.4%) in patients with multiple ipsilateral BC.

Study details: Findings are from the phase 2 American College of Surgeons Oncology Group Z11102 (Alliance) trial including 204 women aged ≥40 years with multiple ipsilateral BC who underwent BCS.

Disclosures: This study was supported by the US National Institutes of Health. Some authors declared owning stocks; serving on editorial boards, in leadership positions, or as employees; receiving research funding, honoraria, or travel and accommodation expenses; or having other ties with various sources.

Source: Boughey JC et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: Results from ACOSOG Z11102 (Alliance). J Clin Oncol. 2023 (Mar 28). Doi: 10.1200/JCO.22.02553

Recommended Reading

CT results in myositis inform cancer screening strategies
MDedge Hematology and Oncology
Commentary: Chemotherapies and gynecologic surgeries relative to breast cancer, April 2023
MDedge Hematology and Oncology
Breast conservation safe even with multiple-site tumors
MDedge Hematology and Oncology
‘Startling’ cost barriers after abnormal screening mammogram
MDedge Hematology and Oncology
De-escalation still beneficial after 10 years for some HER2+ breast cancers
MDedge Hematology and Oncology
Survival improved for some patients with metastatic cancers
MDedge Hematology and Oncology
Outpatient costs top drug costs in some insured, working women with breast cancer
MDedge Hematology and Oncology
AFib risk with cancer drugs underestimated
MDedge Hematology and Oncology
Insurers refusing MRI for women at high risk for breast cancer
MDedge Hematology and Oncology
Stage 0-II ER+ BC: Alternative exemestane dosing regimen noninferior to standard regimen
MDedge Hematology and Oncology